At a glance
| Field | Details |
|---|---|
| Brand names | Ozempic (T2D injection), Wegovy (obesity injection), Rybelsus (T2D oral) |
| Targets | GLP-1R |
| Developer | Novo Nordisk |
| Modality | SC injection weekly / oral tablet daily |
| Approval status | Approved — US, EU, global |
| Key efficacy | 14.9% weight loss at 68 weeks (Wegovy 2.4mg, STEP 1) |
| Indications | Type 2 diabetes, obesity, cardiovascular risk reduction |
User Sentiment
The most common thing semaglutide users report isn't the weight loss — it's the quiet. "Food noise" — the constant background hum of thinking about food, planning the next meal, negotiating snacks — just stops. For many people that's the first sign it's working, before the scale moves at all.
Example(What the community says)
r/WegovyWeightLoss has over 150,000 members comparing notes. The recurring themes: nausea in weeks 1–4 that almost always passes, a plateau around month 3 that scares people into quitting right before it breaks, and the surprise of not being hungry at meals they used to overeat at without thinking.
How it works
A long-acting GLP-1 analog with a C18 fatty acid chain that binds albumin in the bloodstream, extending half-life to approximately 7 days and enabling once-weekly dosing. Three formulations, same molecule: Ozempic and Wegovy are subcutaneous injections at different dose ceilings (1mg for T2D, 2.4mg for obesity), and Rybelsus is an oral tablet requiring specific fasting conditions to achieve adequate gut absorption.
GLP-1R activation drives appetite suppression through hypothalamic and brainstem signaling, glucose-dependent insulin secretion, glucagon suppression, and gastric emptying delay — the same mechanism shared by every drug in the single agonist family, at the highest approved systemic exposure level.
Intuition(Why SELECT changed everything)
Wegovy's 14.9% weight loss mattered to obesity medicine. The SELECT cardiovascular outcome trial mattered to cardiology, internal medicine, and payers. A 20% MACE reduction in obese patients without diabetes is a number that justifies prescribing a $1,000/month drug to someone who has no glycemic problem — it reframes GLP-1 therapy from a weight loss drug to a cardiovascular risk drug. That's a different market.
Trial data
STEP 1 (Wegovy 2.4mg, obesity, non-diabetic, 68 weeks): 14.9% mean weight loss. ~32% of participants lost more than 15% of body weight.
SUSTAIN trials (Ozempic, T2D): ~1.5% HbA1c reduction across doses. Consistently outperformed older agents including exenatide and dulaglutide on both glycemic control and weight.
SELECT trial (cardiovascular outcomes, obesity + CVD, no diabetes): 20% reduction in MACE — the trial that expanded semaglutide from a metabolic drug into cardiology and significantly elevated its market positioning.
SURMOUNT-5 (head-to-head vs tirzepatide 2.4mg, 2025): semaglutide produced ~47% less relative weight loss than tirzepatide — the clearest data point on where semaglutide's ceiling sits relative to the dual agonist generation.
What to Expect
Weeks 1–4 — Nausea is common, especially in the first day or two after injection. Eating smaller portions helps. Most people report it fades significantly by week 3.
Month 2 — The food noise starts going quiet. Appetite reduces noticeably. Weight loss of 2–4% is typical by now.
Month 3–4 — A common plateau. Weight loss slows or stalls. This is normal — the body is adjusting. Most people break through it by month 5.
Month 6+ — The 10–15% weight loss range typically lands here for people on 2.4mg maintenance. Energy and mobility improvements often reported alongside the scale changes.
Dosing and administration
Wegovy: 0.25mg weekly → 0.5mg → 1mg → 1.7mg → 2.4mg maintenance over 16–20 weeks. Single-dose pen.
Ozempic: 0.25mg weekly → 0.5mg maintenance (can escalate to 1mg or 2mg for additional glycemic control).
Rybelsus: 3mg daily for 30 days → 7mg → 14mg. Must be taken on an empty stomach with a small sip of water, 30 minutes before any food or other medication.
Development status
| Milestone | Status |
|---|---|
| Ozempic (T2D) | Approved US 2017 |
| Rybelsus (T2D oral) | Approved US 2019 |
| Wegovy (obesity) | Approved US 2021 |
| SELECT (CVD indication) | Approved 2024 |
| Supply normalization | Ongoing — Novo Nordisk manufacturing investment |
Safety profile
Nausea, vomiting, and diarrhea most common — highest during dose escalation, typically self-resolving within 4–8 weeks. Black box warning for thyroid C-cell tumors based on rodent data (clinical significance in humans unclear, no confirmed human cases). Rare pancreatitis. Worsening of diabetic retinopathy observed in some T2D patients with rapid glycemic improvement. Heart rate increase of ~1–2 bpm (class effect).
Who It's For
- BMI ≥ 30, or BMI ≥ 27 with a weight-related condition (high blood pressure, sleep apnea, type 2 diabetes)
- People with type 2 diabetes looking for weight loss alongside glycemic control
- Adults with cardiovascular disease and obesity — SELECT trial data supports this specifically
- Anyone who's tried lifestyle changes without reaching a sustainable result
A provider visit is the next step — they'll confirm eligibility and walk through which formulation fits your situation.
Summary(The semaglutide picture)
The current standard of care across three formulations, two indications, and one proven cardiovascular outcome. SURMOUNT-5 quantified where it sits vs the next generation — ~47% less relative weight loss than tirzepatide at the same 2.4mg ceiling dose. The benchmark everything else is measured against.